Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.

Weiwei YuWeiqiang LuGuoliang ChenFeixiong ChengHui SuYihua ChenMingyao LiuXiufeng Pang

Published in: British journal of pharmacology (2017)

Our preclinical study of YF454A provides a rationale for combining erlotinib with a histone deacetylase inhibitor to treat NSCLC with EGFR-TKI resistance.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
histone deacetylase
small cell lung cancer
tyrosine kinase
cell therapy
single cell
dna methylation
stem cells
growth factor
signaling pathway
bone marrow
mesenchymal stem cells